Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011, 155(4):355-359 | DOI: 10.5507/bp.2011.042

ADIPOCYTE FATTY ACID BINDING PROTEIN AND C-REACTIVE PROTEIN LEVELS AS INDICATORS OF INSULIN RESISTANCE DEVELOPMENT

Dagmar Horakovaa, Dalibor Pastuchab, David Stejskalc, Helena Kollarovaa, Katerina Azeema, Vladimir Janouta
a Department of Preventive Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Exercise Medicine and Cardiovascular Rehabilitation, Faculty of Medicine and Dentistry, Palacky University Olomouc
c Department of Laboratory Medicine and Metabolic Out Patient Centre, Central Moravian Hospital, Prostejov

Background: Adipocyte fatty acid-binding protein (aFABP) has recently been identified as a potential circulating marker for metabolic syndrome. C-reactive protein (CRP), a sensitive marker of inflammation, is increased in individuals with diabetes and metabolic syndrome due to the development of subclinical inflammation. The study uses logistic regression models to analyze the relations between aFABP and CRP along with other parameters of insulin resistance. The objective was to investigate the potential use of aFABP and CRP levels as tools in the diagnosis of the metabolic syndrome.

Methods and results: The following groups were studied: healthy individuals (A, n=122), obese individuals (B, n=213) and patients diagnosed with metabolic syndrome (C, n=79). Obese persons in Group B had parameters suggestive of early insulin resistance: hypertension, hyperglycaemia, QUICKI (0.305) and higher aFABP levels as compared with the healthy subjects. Group C individuals were diagnosed with metabolic syndrome, as evidenced by the QUICKI markers for insulin resistance (0.293), high aFABP levels (35.3 mg/l). CRP concentrations were lowest in Group A healthy individuals (0.67 mg/l), higher in Group B obese subjects (2.65 mg/l) and highest in Group C patients with metabolic syndrome (3.62 mg/l). Logistic regression models showed an association of aFABP and CRP with BMI (OR 1.12 and 1.39, compared Group A vs C). An association of aFABP and CRP with the QUICKI index showed OR 1.48 and 1.37 (Group A vs C); with triglyceride levels showed OR 1.68 and 1.52 (Group A vs C). An association of aFABP and CRP with glycaemia showed OR 1.48 and 1.51 (Group A vs C), with insulinaemia showed OR 1.44 and 1.38 (Group A vs C) respectively.

Conclusions: AFABP levels were higher in obese individuals and highest in those with metabolic syndrome. CRP concentrations were increased in obese persons whereas individuals with metabolic syndrome were found to have high-risk CRP levels. Logistic regression models showed an association of aFABP and CRP with BMI as well as an association of aFABP and CRP with parameters of insulin resistance, namely the QUICKI index, triglyceride levels, glycaemia and insulinaemia. Both methods are of diagnostic benefit for predicting metabolic syndrome, especially in previously untreated patients.

Keywords: aFABP, CRP, Insulin resistance, Metabolic syndrome, Inflammation, Adiponectin, Obesity

Received: April 20, 2011; Accepted: July 12, 2011; Prepublished online: September 16, 2011; Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horakova, D., Pastucha, D., Stejskal, D., Kollarova, H., Azeem, K., & Janout, V. (2011). ADIPOCYTE FATTY ACID BINDING PROTEIN AND C-REACTIVE PROTEIN LEVELS AS INDICATORS OF INSULIN RESISTANCE DEVELOPMENT. Biomedical papers, 155(4), 355-359. doi: 10.5507/bp.2011.042
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jansson PA. Endothelial dysfunction in insulin resistence and type 2 diabetes. J Intern Med 2007;262(2):173-83. Go to original source... Go to PubMed...
    2. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13. Go to original source... Go to PubMed...
    3. Tso AW, Xu PC, Sham MN, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes. Diab Care 2007;30:2667-72. Go to original source... Go to PubMed...
    4. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109(23):2818-25. Go to original source... Go to PubMed...
    5. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). Washington DC: US Govt. Printing Office 2001, NIH publ. no. 013670. Go to original source...
    6. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10. Go to original source... Go to PubMed...
    7. R Development Core Team (2005). R: A language and environment for statistical computing, reference index version 2.13.0. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
    8. Bo S, Gentile L, Ciccone G, Baldi C, Benini L, Dusio F, Lucia C, Forastiere G, Nuti C, Cassader M, Franco Pagano G. The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 2005;21(6):515-24. Go to original source... Go to PubMed...
    9. Stefanska A, Sypniewska G, Blaszkiewicz N, Ponikowska I, Cwiklinska-Jurkowska M. Comparison between C-reactive protein and adipocyte fatty acid-binding protein as a component of metabolic syndrome in middle-aged women. Clin Biochem 2011;44(4):304-6. Go to original source... Go to PubMed...
    10. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009;20(3):182-9. Go to original source... Go to PubMed...
    11. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Janout V. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007;37(8):637-42. Go to original source... Go to PubMed...
    12. Choi KM, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH, Hwang TG, Yang SJ, Kim TN, Yoo HJ, Baik SH, Kim SM, Mantzoros CS. Serum adipocyte fatty acid-binding protein, retinolbinding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr 2011;93(1):19-26. Go to original source... Go to PubMed...
    13. Ye WH, Peng X H, Ai YQ, Chen H. Relations between serum adipocyte fatty acid-binding protein and type 2 diabetes in a community population. Nan Fang Yi Ke Da Xue Xue Bao, 2011;31(3):508-11. Go to PubMed...
    14. Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M. FABP is associated with inflammatory markers and metabolit syndrome in morbidly obese women. Eur J Endocrinol 2011;164(4):539-47. Go to original source... Go to PubMed...
    15. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from A Diabetes Outcome Progression Trial (ADOPT). Diab Care 2010;33(1):177-83. Go to original source... Go to PubMed...
    16. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28(5):674-9. Go to original source... Go to PubMed...
    17. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 2006;36(9):621-5. Go to original source... Go to PubMed...

    Return to the content